


Docket No. P50533-03



PATENT

GP. 1652
#11
UE
326A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Burnham, et al.
Serial No.: 08/896,589
Filing Date: July 17, 1997
For: Novel Xanthine
Phosphoribosyl Transferase

Art Unit: 1652
Examiner: Stole

MAR 15 1999
GROUP 1800

Assistant Commissioner for Patents
Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 5, 1999.

By:

Heather S. Richman

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the references, listed on Form PTO-1449 (PTO-2), in accordance with 37 CFR 1.98(a)(2).

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Supplemental Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1) This Supplemental Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the patent application.
- ☐ within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.

03/11/1999 RMAGAT 00000162 500258 08896589

01 FC:126 240.00 CH

- ☐ **before** the mailing date of a first Office Action on the merits.
- ☒ **after** the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:
- ☐ the Statement under 37 CFR 1.97(e) (see "Statement" below);
- or**
- ☒ the Fee of \$240.00 set forth in 37 CFR 1.17(p); or
- ☐ No fee is owed by the applicants.
- ☐ **after** the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Supplemental Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).

(2) **Statement**

- ☐ The **undersigned attorney** hereby states that each item information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

(If this box is checked, do not check any further Statement boxes.)


or

- ☐ The **person signing immediately below** hereby states that no item of information contained in the Supplemental Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

The person making the statement is:

- ☐ the undersigned attorney who signs on the basis of the information:

- ☐ supplied by the inventor(s).
- ☐ supplied by an individual designated in 37 CFR 1.56(c).
- ☐ in the attorney's file.



Signature of the Attorney

(3) **Petition**

- ☐ Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Supplemental Information Disclosure Statement and on the enclosed Form PTO-1449, in the examination of the above-identified patent application.

(4) **Fees**

- ☐ No Fee is owed by the applicants.
- ☒ The IDS Fee of \$240.00 under 37 CFR 1.17(p) is enclosed herewith.
- ☐ The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(5) **Method of Payment of Fees**

- ☐ Attached is a check in the amount of \$_____.
- ☒ Charge Account No. 50-0258 in the amount of \$240.00. (A duplicate of this request is attached).

(6) **Authorization to Charge Additional Fees**


- ☒ If any additional fees are owed in connection with this communication, please charge Deposit Account No. 05-0258.

(7) **Instructions as to Overpayment**

- ☒ Please credit Account No. 05-0258 for any overpayment.
- ☐ Please refund Dechert Price & Rhoads in the amount of \$_____.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,



Andrew L. Fish
Registration No. 40,605
Attorney for Applicant(s)

Date: March 5, 1999

DECHERT PRICE & RHOADS
4000 Bell Atlantic Tower
1717 Arch Street
Philadelphia, PA 19103-2793
Tel: (215) 994-2643